Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsBiology of Blood and Marrow Transplantation.  25:233-238. 2019
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaBiology of Blood and Marrow Transplantation.  24:1379-1385. 2018
2017 Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaBiology of Blood and Marrow Transplantation.  23:269-277. 2017
2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failureBone Marrow Transplantation.  52:157-158. 2017
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
2015 Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia is it ready for "prime time"?Journal of the American Medical Association.  313:571-572. 2015
2015 Paradigm shifts in the management of poor-risk chronic lymphocytic leukemiaLeukemia & Lymphoma.  56:1626-1635. 2015

Investigator On

  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation 2019 - 2024
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by BLUEBIRD BIO INC. 2019 - 2021
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC. 2013 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2018
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2014 - 2018
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS 2014 - 2018
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan 2012 - 2016
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University 2014 - 2015
  • Education And Training

  • Doctor of Medicine in Internal Medicine Residency Program, Medical College of Georgia 1998
  • Atlanta Medical Center, Internship 1999
  • Atlanta Medical Center, Residency 2001
  • UAB Hospital, Postdoctoral Fellowship 2009
  • University of Virginia Hospital, Postdoctoral Fellowship 2008
  • Full Name

  • Racquel Innis-Shelton